Rhythm Pharmaceuticals, Inc. (RYTM) — Analyst outlook / Analyst consensus target is. Based on 20 analyst ratings, the consensus is bullish — 20 Buy.
The consensus price target is $140.00 (low: $125.00, high: $157.00), representing an upside of 60.4% from the current price $87.28.
Analysts estimate Earnings Per Share (EPS) of $-4.32 and revenue of $0.13B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.21 vs est $-4.32 (beat +2.6%). 2025: actual $-3.11 vs est $-3.17 (beat +2%). Analyst accuracy: 98%.
RYTM Stock — 12-Month Price Forecast
$140.00
▲ +60.40% Upside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Rhythm Pharmaceuticals, Inc., the average price target is $140.00, with a high forecast of $157.00, and a low forecast of $125.00.
The average price target represents a +60.40% change from the last price of $87.28.
Highest Price Target
$157.00
Average Price Target
$140.00
Lowest Price Target
$125.00
RYTM Analyst Ratings
Buy
Based on 20 analysts giving stock ratings to Rhythm Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — RYTM
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.21
vs Est –$4.32
▲ 2.7% off
2025
Actual –$3.11
vs Est –$3.17
▲ 2.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RYTM
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.130B
vs Est $0.127B
▲ 2.4% off
2025
Actual $0.190B
vs Est $0.189B
▲ 0.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
